How Lowering The Price of a Common Asthma Drug Made it Harder to Get

To avoid Medicaid penalties, Glaxo and other drugmakers lowered prices. For popular asthma drug Flovent HFA, the tactic to replace it with a generic backfired.

Related Keywords

,Wsjhealth ,Pharmaceuticals ,Respiratory Allergy Treatments ,Insurance ,Non Life Insurance ,Health Medical Insurance ,Healthcare Life Sciences ,Specialized Drugs Medications ,Financial Services ,Government Sponsored Health Insurance ,Healthcare Support Services ,Pharmacy Benefit Management ,North America ,United States ,Prices ,Corporate Industrial News ,Markets Marketing ,Asthma ,Political General News ,Respiratory Tract Diseases ,Demographic Health ,Health ,Infant Child Teenage Health ,Medical Conditions ,Synd ,Wsj Pro Com ,Eli Lilly ,Rally ,Novo Nordisk ,Novob Ko ,Dk Novo B ,Sanofi ,San Fr ,Fr San ,Gsk ,Gsk Ln ,Uk Gsk ,Unitedhealth Group ,Unh ,Link I2 Wp Wsj 0001459961 ,Link I4 Wp Wsj 0001459961 ,Link I5 Wp Wsj 0001459961 ,Link I3 Wp Wsj 0001459961 ,Corporate ,Industrial News ,Markets ,Marketing ,Political ,General News ,Infant ,Child ,Teenage Health ,Respiratory ,Allergy Treatments ,Medical Insurance ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,